About Rezdiffra Rezdiffra is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. It is the first approved medication for the treatment of MASH in the US ...

The SmartVascular Dx test is essential for the early detection of vascular disease, which is a significant health concern in many communities. Its capabilities enable timely and targeted interventions ...

The financing consists of a combination of a $36 million line of credit and a $14 million contingent private placement. The line of credit is available immediately and allows Tevogen Bio to access up ...

NMDP Unite brings together blood stem cell donors, transplant recipients, caregivers, and supporters, all united by one mission: to find cures and give hope to patients facing life-threatening blood ...

JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza ...

"This move by the Board of Directors aligns with our current goal of reducing the share count." said Giorgio R. Saumat, CEO of ETST. "It sends a clear signal to the investment community: we are ...

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635 (c) (4).

Operating expenses decreased $63,300, or 2.4%, to $2,565,300 and $364,900 or 6.3%, respectively in the three-month and six-month periods ended June 30, 2025, compared to $2,628,600 and $5,758,900, ...

Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective ...

Investment to support NovaBay’s continued public listing and provide funding for a future strategic transaction ...

Since 2020, patients from all over the world—including nearly 60% traveling from outside the United States—have sought Dr.

MedX Holdings, Inc. (OTC: MEDH) Med-X Holdings Q2 2025 Investor Update: We’re at an Inflection Point Sales up; on track for ~$1.5M FY25 revenue. Las Vegas lounge approaching approvals. Leaf-trak POS ...